We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+68.44%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$209M
AUM Growth
+$61.8M
Cap. Flow
+$2.58M
Cap. Flow %
1.24%
Top 10 Hldgs %
85.87%
Holding
21
New
3
Increased
4
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$3.82M
2
BLU
BELLUS Health Inc.
BLU
+$3.34M
3
LQDA icon
Liquidia Corp
LQDA
+$3.23M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$2.5M
5
PVLA
Palvella Therapeutics
PVLA
+$2.44M

Top Sells

Rank Stock Value
1
GOSS icon
Gossamer Bio
GOSS
+$6.32M
2
ALLK
Allakos
ALLK
+$3.93M
3
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$2.86M
4
EVLO
Evelo Biosciences, Inc. Common Stock
EVLO
+$1.39M
5
SWTX
SpringWorks Therapeutics
SWTX
+$541K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ICPT
1
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$50M 23.97%
403,688
– –
SWTX
2
DELISTED
SpringWorks Therapeutics
SWTX
$25.2M 12.05%
653,502
-23,100
-3% -$541K
ALLK
3
DELISTED
Allakos
ALLK
$23.1M 11.08%
242,505
-44,700
-16% -$3.93M
ODT
4
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$17M 8.13%
522,637
– –
PRNB
5
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$16.8M 8.05%
306,784
-76,696
-20% -$2.86M
STRO icon
6
Sutro Biopharma
STRO
$379M
$12.4M 5.93%
112,558
– –
SYRS
7
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$11.3M 5.39%
172,660
– –
BCEL
8
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$9.15M 4.38%
591,368
– –
ARAV
9
DELISTED
Aravive, Inc. Common Stock
ARAV
$7.88M 3.77%
576,066
+133,333
+30% +$1.18M
HOOK
10
DELISTED
HOOKIPA Pharma
HOOK
$6.49M 3.11%
53,025
– –
ISEE
11
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$6.01M 2.88%
+700,000
New +$2.5M
TPST icon
12
Tempest Therapeutics
TPST
$14.8M
$4.82M 2.31%
3,668
+2,711
+283% +$3.82M
LQDA icon
13
Liquidia Corp
LQDA
$7.67B
$4.1M 1.96%
958,466
+804,004
+521% +$3.23M
BLU
14
DELISTED
BELLUS Health Inc.
BLU
$3.69M 1.77%
+488,858
New +$3.34M
PVLA
15
Palvella Therapeutics
PVLA
$1.98B
$2.55M 1.22%
+8,803
New +$2.44M
UROV
16
DELISTED
Urovant Sciences Ltd.
UROV
$2.44M 1.17%
157,480
– –
KALV
17
DELISTED
KalVista Pharmaceuticals
KALV
$2.11M 1.01%
118,500
– –
VIRX
18
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2M 0.96%
169,663
+66,494
+64% +$1.11M
ATXS
19
DELISTED
Astria Therapeutics
ATXS
$1.77M 0.85%
50,000
– –
GOSS icon
20
Gossamer Bio
GOSS
$66.5M
– –
-376,583
Closed -$6.32M
EVLO
21
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
– –
-11,376
Closed -$1.39M

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
RIM
RW Investment Management Eagle, Idaho $1.03B AUM
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return

Samsara BioCapital's Q4 2019 Portfolio in Review

As of Q4 2019, Samsara BioCapital held 21 positions worth $209M, up 42% from $147M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Samsara BioCapital's Q4 2019 filing shows 3 new, 4 increased, 3 reduced and 2 closed positions. Its largest new stake was BELLUS Health Inc.: 488,858 shares worth $3.69M. The largest sale was Gossamer Bio, an estimated $6.32M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Samsara BioCapital's largest Q4 2019 buy was BELLUS Health Inc.: 488,858 shares worth $3.69M.
  • Samsara BioCapital added most to Tempest Therapeutics in Q4 2019, an estimated $3.82M increase.
  • Samsara BioCapital's biggest Q4 2019 reduction was Allakos, cutting an estimated $3.93M.
  • Samsara BioCapital fully exited Gossamer Bio in Q4 2019, selling an estimated $6.32M.
  • Samsara BioCapital's ten largest holdings make up 86% of its $209M portfolio in Q4 2019.
  • Samsara BioCapital opened 3 new positions and closed 2 in Q4 2019.
  • Samsara BioCapital's portfolio value rose 42% quarter-over-quarter to $209M.

Based on Samsara BioCapital's 13F filing for Q4 2019, filed 18 Feb 2020.